<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30278051</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.</ArticleTitle><Pagination><StartPage>e0202552</StartPage><MedlinePgn>e0202552</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0202552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0202552</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a major etiological agent of various public health issues, particularly in the Asia-Pacific region. EV71 causes hand-foot-and-mouth disease (HFMD) and is associated with serious neurological disorders in young children. A formalin-inactivated EV71 candidate vaccine (KCDC-HFMDV1-EV71) based on the C4 subgenotype was previously developed and confirmed to be a potential candidate vaccine for prevention of EV71 infection in mice. In this study, an inactivated EV71 vaccine was used for analysis of long-term immunogenicity and efficacy in cynomolgus monkeys, a common nonhuman primate model. The vaccine was immunized three times at 0, 4, and 8 weeks with either 20-&#x3bc;g doses of EV71 candidate vaccine formulated with aluminum hydroxide gel adjuvant or phosphate-buffered saline as a control. The group immunized with the inactivated EV71 showed significantly increased EV71-specific antibody and serum neutralizing antibody titers at 3 weeks after vaccination and maintained these elevated titers until the end of the experiment (54 weeks after vaccination). The sera from vaccinated cynomolgus monkeys showed a crossreactive neutralizing antibody response to the heterologous subtype of EV71 (B1-4, C1, and C2). These findings suggest that the inactivated EV71 candidate vaccine may be a potential vaccine candidate and valuable tool for the control of HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>In</LastName><ForeName>Hyun Ju</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Heeji</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jung-Ah</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Rae</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>The National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yeung Bae</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>The National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Kang-Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>The National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyeon</LastName><ForeName>Ji-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jung Sik</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>June-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Young Ki</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Won</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0003-0027-0134</Identifier><AffiliationInfo><Affiliation>Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30278051</ArticleId><ArticleId IdType="pmc">PMC6168120</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0202552</ArticleId><ArticleId IdType="pii">PONE-D-17-34420</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious diseases. 2010;10(11):778&#x2013;90. Epub 2010/10/22. 10.1016/S1473-3099(10)70194-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerging infectious diseases. 2003;9(4):461&#x2013;8. Epub 2003/04/19. 10.3201/eid0904.020395 ; PubMed Central PMCID: PMCPMC2957976.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood). 2011;236(8):899&#x2013;908. Epub 2011/07/01. 10.1258/ebm.2010.010233 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2010.010233</ArticleId><ArticleId IdType="pubmed">21715436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Zhou B, Zhang MX, Tsoi HW, Chan KH, et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol. 2010;155(9):1413&#x2013;24. Epub 2010/06/16. 10.1007/s00705-010-0722-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-010-0722-0</ArticleId><ArticleId IdType="pmc">PMC7087135</ArticleId><ArticleId IdType="pubmed">20549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304&#x2013;9. Epub 1974/03/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133(6):795&#x2013;8. Epub 1998/12/08. .</Citation><ArticleIdList><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929&#x2013;35. Epub 1999/09/25. 10.1056/NEJM199909233411301 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, et al. Enterovirus 71 outbreak in the People's Republic of China in 2008. Journal of clinical microbiology. 2009;47(7):2351&#x2013;2. Epub 2009/05/15. 10.1128/JCM.00563-09 ; PubMed Central PMCID: PMCPMC2708525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00563-09</ArticleId><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerging infectious diseases. 2003;9(3):291&#x2013;3. Epub 2003/03/20. 10.3201/eid0903.020285 ; PubMed Central PMCID: PMCPMC2963902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0903.020285</ArticleId><ArticleId IdType="pmc">PMC2963902</ArticleId><ArticleId IdType="pubmed">12643822</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J. 2013;6:19780 Epub 2013/10/15. 10.3402/ehtj.v6i0.19780 ; PubMed Central PMCID: PMCPMC3772321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002;109(6):e88 Epub 2002/06/04. .</Citation><ArticleIdList><ArticleId IdType="pubmed">12042582</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60(4):466&#x2013;71. Epub 2006/08/31. 10.1203/01.pdr.0000238247.86041.19 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Wang SW, Tung YY, Chen SH. Enterovirus 71 infection of human dendritic cells. Exp Biol Med (Maywood). 2009;234(10):1166&#x2013;73. Epub 2009/07/15. 10.3181/0903-rm-116 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/0903-rm-116</ArticleId><ArticleId IdType="pubmed">19596831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-N, Lin Y-C, Fann C, Liao N-S, Shih S-R, Ho M-S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20(5&#x2013;6):895&#x2013;904. 10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81(17):9386&#x2013;95. Epub 2007/06/15. 10.1128/JVI.02856-06 ; PubMed Central PMCID: PMCPMC1951441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9(11):1299&#x2013;306. Epub 2007/09/25. 10.1016/j.micinf.2007.06.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26(15):1855&#x2013;62. Epub 2008/03/11. 10.1016/j.vaccine.2008.01.058 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010;28(43):6951&#x2013;7. Epub 2010/08/28. 10.1016/j.vaccine.2010.08.052 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A-H, Liu C-C, Chang J-Y, Jiang R, Hsieh Y-C, Tsao A, et al. Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLOS ONE. 2013;8(11):e79783 10.1371/journal.pone.0079783</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079783</ArticleId><ArticleId IdType="pmc">PMC3836818</ArticleId><ArticleId IdType="pubmed">24278177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2013;381(9882):2024&#x2013;32. Epub 2013/06/04. 10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh S-Y, Liu C-C, Chou A-H, Chang J-Y, Wu S-C, et al. Production of EV71 vaccine candidates. Human Vaccines &amp; Immunotherapeutics. 2012;8(12):1775&#x2013;83. 10.4161/hv.21739 PubMed PMID: PMC3656065.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013;31(20):2471&#x2013;6. Epub 2013/04/02. 10.1016/j.vaccine.2013.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012;30(22):3295&#x2013;303. Epub 2012/03/20. 10.1016/j.vaccine.2012.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.03.010</ArticleId><ArticleId IdType="pubmed">22426327</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamanti E, Ibrahimi B, Tafaj F, Mezini E, Dodbiba A, Dobi V, et al. Surveillance of suspected poliomyelitis in Albania, 1980&#x2013;1995: suggestion of increased risk of vaccine associated poliomyelitis. Vaccine. 1998;16(9&#x2013;10):940&#x2013;8. Epub 1998/07/31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9682341</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol. 2003;13(5):277&#x2013;91. Epub 2003/08/22. 10.1002/rmv.401</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.401</ArticleId><ArticleId IdType="pubmed">12931339</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner BG, Earn DJ. Circulating vaccine derived polio viruses and their impact on global polio eradication. Bull Math Biol. 2008;70(1):253&#x2013;80. Epub 2007/10/16. 10.1007/s11538-007-9255-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11538-007-9255-4</ArticleId><ArticleId IdType="pubmed">17934778</ArticleId></ArticleIdList></Reference><Reference><Citation>In HJ, Lim H, Lee JA, Kim HJ, Kim JW, Hyeon JY, et al. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. PLoS One. 2017;12(5):e0178259 Epub 2017/05/26. 10.1371/journal.pone.0178259 PubMed Central PMCID: PMCPMC5443535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0178259</ArticleId><ArticleId IdType="pmc">PMC5443535</ArticleId><ArticleId IdType="pubmed">28542556</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. Journal of biomedical science. 2014;21:31 Epub 2014/04/20. 10.1186/1423-0127-21-31 PubMed Central PMCID: PMCPMC4013435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-31</ArticleId><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011;29(37):6269&#x2013;75. Epub 2011/07/05. 10.1016/j.vaccine.2011.06.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.044</ArticleId><ArticleId IdType="pubmed">21722686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou XB, Lu JJ, Jiang YS, Huo Y, Wang JF, Zhou KF, et al. A safety study of inactivated Enterovirus 71 vaccine. Hum Vaccin Immunother. 2013;9(7):1430&#x2013;7. Epub 2013/04/11. 10.4161/hv.24395</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24395</ArticleId><ArticleId IdType="pubmed">23571172</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Hwang CS, Yang WS, Tsai DC, Wu SH, Chou AH, et al. Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques. PLoS One. 2014;9(9):e106756 Epub 2014/09/10. 10.1371/journal.pone.0106756 PubMed Central PMCID: PMCPMC4157806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106756</ArticleId><ArticleId IdType="pmc">PMC4157806</ArticleId><ArticleId IdType="pubmed">25197967</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015;33(44):6017&#x2013;24. Epub 2015/08/15. 10.1016/j.vaccine.2015.05.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang L, Liao Y, Liu L, Ma K, Yang E, et al. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children. Vaccine. 2015;33(46):6290&#x2013;7. Epub 2015/10/01. 10.1016/j.vaccine.2015.09.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.09.047</ArticleId><ArticleId IdType="pubmed">26419198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30(7):1305&#x2013;12. Epub 2012/01/05. 10.1016/j.vaccine.2011.12.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>